PMID- 27053004
OWN - NLM
STAT- MEDLINE
DCOM- 20170928
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 32
IP  - 8
DP  - 2016 Aug
TI  - Association between hypoglycemia risk and hemoglobin A1C in patients with type 2 
      diabetes mellitus.
PG  - 1409-16
LID - 10.1080/03007995.2016.1176017 [doi]
AB  - OBJECTIVE: To better manage type 2 diabetes mellitus (T2DM), the tradeoff between 
      improved glycemic control and hypoglycemia should be evaluated. The purpose of 
      this study was to assess the relationship between hypoglycemia and hemoglobin A1c 
      (HbA1c) in a real-world population. RESEARCH DESIGN AND METHODS: Real-Life 
      Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) was a 
      multi-center, observational study. Patients >/=30 years old using any oral 
      anti-hyperglycemic agent were recruited from seven European and five Asian 
      countries between 2006 and 2007. Hypoglycemia events were collected through 
      patient-reported questionnaires. HbA1c data was collected through chart review. 
      Logistic regression was performed to assess the relationship between hypoglycemia 
      and the most proximate HbA1c levels adjusting for potential confounders 
      (demographics, clinical variables, other medication use, and comorbid 
      conditions). RESULTS: A total of 4399 patients were recruited and analyzed. Mean 
      age was 60 years, 52% were male, and 75% were on sulfonylureas (S.U.s). 
      Respectively, 37% or 42% of patients reported hypoglycemia in the past 6 (Asia) 
      or 12 months (Europe) before recruitment. Prevalence of hypoglycemia increased 
      significantly (33% to 40%) as HbA1c decreased (p = 0.035). The same trend was 
      also observed among S.U.-treated patients (p < 0.01). After adjusting for 
      confounders, hypoglycemia prevalence was significantly higher for HbA1c <7.0% 
      (odds ratio [O.R.] = 1.66 [95% C.I. 1.21, 2.28]; p = 0.002) vs. HbA1c >/=10.0%. 
      LIMITATIONS: Our analyses pooled data from Asia and Europe, which differed in 
      terms of the recall period for ascertaining hypoglycemia symptoms and the timing 
      of latest HbA1c measure. CONCLUSIONS: Lower HbA1c level was associated with 
      higher hypoglycemia prevalence among S.U.-treated patients. HbA1c level should be 
      taken into consideration when reporting hypoglycemia prevalence.
FAU - Yu, Shengsheng
AU  - Yu S
AD  - a Abbott Diabetes Care, Inc. , Alameda , CA , USA. ;
FAU - Fu, Alex Z
AU  - Fu AZ
AD  - b Georgetown University Medical Center , Washington , DC , U.S.A.
FAU - Engel, Samuel S
AU  - Engel SS
AD  - a Abbott Diabetes Care, Inc. , Alameda , CA , USA. ;
FAU - Shankar, R Ravi
AU  - Shankar RR
AD  - a Abbott Diabetes Care, Inc. , Alameda , CA , USA. ;
FAU - Radican, Larry
AU  - Radican L
AD  - a Abbott Diabetes Care, Inc. , Alameda , CA , USA. ;
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20160505
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Hypoglycemia/*epidemiology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Sulfonylurea Compounds/*therapeutic use
OTO - NOTNLM
OT  - Glycemic control
OT  - HbA1c
OT  - hypoglycemia
OT  - sulfonylureas
OT  - type 2 diabetes
EDAT- 2016/04/08 06:00
MHDA- 2017/09/29 06:00
CRDT- 2016/04/08 06:00
PHST- 2016/04/08 06:00 [entrez]
PHST- 2016/04/08 06:00 [pubmed]
PHST- 2017/09/29 06:00 [medline]
AID - 10.1080/03007995.2016.1176017 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2016 Aug;32(8):1409-16. doi: 10.1080/03007995.2016.1176017. 
      Epub 2016 May 5.